Your SlideShare is downloading. ×
0
Multiple myeloma
Multiple myeloma
Multiple myeloma
Multiple myeloma
Multiple myeloma
Multiple myeloma
Multiple myeloma
Multiple myeloma
Multiple myeloma
Multiple myeloma
Multiple myeloma
Multiple myeloma
Multiple myeloma
Multiple myeloma
Multiple myeloma
Multiple myeloma
Multiple myeloma
Multiple myeloma
Multiple myeloma
Upcoming SlideShare
Loading in...5
×

Thanks for flagging this SlideShare!

Oops! An error has occurred.

×
Saving this for later? Get the SlideShare app to save on your phone or tablet. Read anywhere, anytime – even offline.
Text the download link to your phone
Standard text messaging rates apply

Multiple myeloma

439

Published on

Multiple myeloma is the most common primary malignant bone tumor in the world. It is usually seen in elderly individuals of >40 years. In this presentation, all the important aspects of Multiple …

Multiple myeloma is the most common primary malignant bone tumor in the world. It is usually seen in elderly individuals of >40 years. In this presentation, all the important aspects of Multiple myeloma have been discussed extensively and in brief..

Published in: Health & Medicine
0 Comments
2 Likes
Statistics
Notes
  • Be the first to comment

No Downloads
Views
Total Views
439
On Slideshare
0
From Embeds
0
Number of Embeds
1
Actions
Shares
0
Downloads
48
Comments
0
Likes
2
Embeds 0
No embeds

Report content
Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
No notes for slide

Transcript

  • 1. MULTIPLE MYELOMA PRITHWIRAJ MAITI FINAL YEAR MBBS R.G.KAR MEDICAL COLLEGE 5.3.2014
  • 2. Introduction • It is the most common primary malignant bone tumor. • Age: It is seen primarily in elderly, in people of >40 years. • Male gender affected more than female. • Bones affected: Flat bones (Pelvis, vertebrae, skull, ribs).
  • 3. Pathogenesis • Multiple myeloma is a B cell lymphoproliferative disorder with plasma cell predominant. • There is extensive proliferation of marrow cells. • There is increased osteoclastic activity, resulting in osteoporosis and discrete lytic lesions.
  • 4. Clinical features • Multiple myeloma usually follows a chronic course. • Initially the disease is silent, after which the patient presents with pain on lumber and thoracic spine (back pain), which is progressively increasing in severity. • Sometimes patient presents with pathological fractures of vertebra and ribs, where acute presentation (pain, redness, swelling etc) is observed. • Weakness (due to anemia). • Loss of weight. • Local bone tenderness. • Neurological symptoms (from compression of spinal cord/ nerve root) may also be seen.
  • 5. Other associated features • Hypercalcemia (due to osteoclastic activity): Thirst, Polyuria, Abdominal pain. • Acute/ chronic renal failure. • Chronic nephritis. • Recurrent infection.
  • 6. Pathology • • • • Soft and crumbly in consistency. Dark red in colour. Usually located in medulla. Cortex overlying the tumor is thin and broken.
  • 7. Microscopy • Closely packed round cells. • Eccentric nucleus and nucleolus. • Chromatin: “Spokes of wheel” appearance.
  • 8. Radiology • Multiple punched out lesion in skull and other bones. • Pathological wedge collapse in vertebrae (Pedicle sign). • Erosion of borders of ribs.
  • 9. Relevant investigations • Blood: Severe anemia, Very high ESR, High total serum protein, High serum calcium level, Reversal of Albumin: Globulin ratio (normal 1.7:1), Normal Alkaline Phosphatase level. (MCQ)
  • 10. • Urine: Bence-Jones proteinuria (Ig light chain). • Serum electrophoresis: M band. (γ-globulin). • Sternal puncture: Myeloma cell.
  • 11. Other investigations • Bone biopsy (CT guided: from iliac crest). • Bone scan. • Open biopsy.
  • 12. TREATMENT • • • • GENERAL MEASURES Control of pain. Supportive treatment: Fluid-electrolyte balance. Limb fracture: Plaster/ splint/ surgery. Vertebral fracture: Bracing/ surgery.
  • 13. RADIOTHERAPY • It is applied only in cases of solitary plasmacytoma.
  • 14. • • • • CHEMOTHERAPY Melphalan is the drug of choice (MCQ). Melphalan is an alkylating agent. It sticks to one of the cancer cell's DNA strands and stops replication. It is often used concurrently with Vincristine/ Prednisolone/ Cyclophosphamide. 6-12 cycles of chemotherapy are given; the duration between two cycles being 3-4 weeks.
  • 15. Prognosis • Multiple myeloma is a widespread disease and fatal. • Death occurs in the majority of patients within 3 years and in all patients within 5 years.
  • 16. Complications of Multiple myeloma • Pathological fractures. • Spinal cord compression and neurological complications. • Anemia/ leucopenia/ thrombocytopenia. • Severe infections. • Renal failure. • Amyloidosis.

×